Bio-Techne Corporation
TECH
Rang in aandelen
#1874
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Aandeelprijs
$72.55
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$11.38B
Verandering (1 dag)
0.03%
Verandering (1 jaar)
17.27%
Land
US
Handel Bio-Techne Corporation (TECH)
Categorie
Healthcare
Operationele marge voor Bio-Techne Corporation (TECH)
Operationele marge op October 2026 TTM: 20.73%
Volgens de meest recente financiële rapporten en aandelenkoers van Bio-Techne Corporation is de huidige operationele marge (TTM) 20.73%. Eind 2024 had het bedrijf een operationele marge van 17.83%.
Geschiedenis van de operationele marge van Bio-Techne Corporation van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 20.73% | 147.37% |
| 2025 | 8.38% | -53.00% |
| 2024 | 17.83% | -32.21% |
| 2023 | 26.30% | -1.98% |
| 2022 | 26.83% | 67.06% |
| 2021 | 16.06% | 58.85% |
| 2020 | 10.11% | -42.52% |
| 2019 | 17.59% | -16.95% |
| 2018 | 21.18% | -2.08% |
| 2017 | 21.63% | -28.33% |
| 2016 | 30.18% | -7.17% |
| 2015 | 32.51% | -27.19% |
| 2014 | 44.65% | -12.49% |
| 2013 | 51.02% | -3.44% |
| 2012 | 52.84% | -6.03% |
| 2011 | 56.23% | -3.22% |
| 2010 | 58.10% | 1.72% |
| 2009 | 57.12% | 1.91% |
| 2008 | 56.05% | 0.90% |
| 2007 | 55.55% | 3.73% |
| 2006 | 53.55% | -2.14% |
| 2005 | 54.72% | 7.25% |
| 2004 | 51.02% | 9.25% |
| 2003 | 46.70% | 15.74% |
| 2002 | 40.35% | 1.61% |
| 2001 | 39.71% | 4.80% |
| 2000 | 37.89% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -98.14% |
US
|
|
| -149.01% | -107.19% |
US
|
|
| 25.57% | -98.77% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.